Hansa Biopharma Reports Promising 12-Month Results for Next-Gen IgG-Cleaving Therapy in Autoimmune Diseases
Time to read: 01:01minutes. The study demonstrated that HNSA-5487 rapidly reduced IgG levels by over 95% within hours of treatment, with levels returning to normal range six months after initial dosing. Importantly, no serious adverse events were observed, and the treatment was found to be safe and well-tolerated.
